Cita APA

Dongo , V. (2023). Budgetary impact of emicizumab versus activated prothrombin complex concentrate (aPCC) for the prophylactic treatment of hemophilia A with inhibitors.

Citación estilo Chicago

Dongo , Victor. Budgetary Impact of Emicizumab Versus Activated Prothrombin Complex Concentrate (aPCC) for the Prophylactic Treatment of Hemophilia A With Inhibitors. 2023.

Cita MLA

Dongo , Victor. Budgetary Impact of Emicizumab Versus Activated Prothrombin Complex Concentrate (aPCC) for the Prophylactic Treatment of Hemophilia A With Inhibitors. 2023.